| Literature DB >> 25947157 |
Michel H Steenks1,2, Gabriella Giancane3, Rob R J de Leeuw4, Ewald M Bronkhorst5, Robert J J van Es6, Ron Koole7, H Willemijn van Bruggen8,9, Nico M Wulffraat10.
Abstract
BACKGROUND: In Juvenile Idiopathic Arthritis (JIA) the temporomandibular joint (TMJ) can be involved leading to pain, dysfunction and growth disturbances of the mandible and associated structures. There may be value to a three minute screening protocol allowing the rheumatologist to detect TMJ involvement systematically. Reliability and validity of the TMJ protocol for detecting TMJ co-morbidity were determined in 74 consecutive JIA patients.Entities:
Mesh:
Year: 2015 PMID: 25947157 PMCID: PMC4437439 DOI: 10.1186/s12969-015-0011-2
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Patient characteristics
|
|
|
|
| |
|---|---|---|---|---|
| Examined | 76 | |||
| Enrolled (F:M) | 74 (2.4:1) | |||
| Age (SD) yrs | 11.9 | 3.8 | ||
| Age at onset (SD) yrs | 7.5 | 3.9 | ||
| Disease duration (SD) yrs | 4.5 | 3.4 | ||
| JIA diagnosis: | ||||
| Oligo ANA pos | 17/23% | |||
| Oligo ANA neg | 15/20.3% | |||
| Oligo extended | 6 /8.1% | |||
| Poly RF pos | 16/21.6% | |||
| Poly RF neg | 8/10.8% | |||
| Systemic JIA | 8 (10.8)% | |||
| ERA HLA B27 pos | 3/4% | |||
| Psoriatic Arthritis | 1/1.4% | |||
| Medication: | ||||
| NSAID | 36/48.6% | |||
| Systemic steroids | 4/5.4% | |||
| DMARDS | 41/55.4% | |||
| Biologics | 22/29.7% | |||
| Orthodontic tx | 7/9.5% | |||
| JADAS-27 | 74 | 3.6 | 5.8 | 0 – 37.5 |
| MMO | 74 | 45.3 | 7.7 | 25 – 60 |
| MMO age ≤ 10 | 27 | 43.6 | 5.4 | 25 – 52 |
| MMO age > 10 | 47 | 46.3 | 8.7 | 25 – 60 |
| MMO ≤ 40 | 21 | 35.9 | 4.2 | 25 – 40 |
| MMO ≤ 35 | 8 | 32.1 | 4.5 | 25 – 35 |
| MMO ≤ 30 | 2 | - | - | 25 – 27 |
Number of patients referred to as n / % (unless indicated otherwise), and MMO as mm
Pt: patients; F: female; M: male; yrs: years, SD = standard deviation, n = number of patients. ANA: anti-nuclear antibodies; oligo: oligoarticular; poly: polyarticular; ERA: enthesitis-related arthritis; PsoA: psoriatic arthritis; NSAIDs: non-steroidal anti-inflammatory drugs; DMARDs: disease modifying anti-rheumatic drugs. Orthodontic tx: coincidental orthodontic treatment (patients being in treatment and wearing appliances not for JIA related TMJ issues). MMO: maximum mouth opening; JADAS-27: Juvenile Arthritis Disease Activity Score.
Figure 1Format of the TMJ screening protocol.
Figure 2Measurement of parameters of maximum mouth opening (a) range of motion (b) lateral deviation on MMO > 2mm; in this illustration there is no lateral deviation.
Reliability (Cohen’s Kappa) of the TMJ screening protocol assessments and prevalence of findings
|
|
|
| |
|---|---|---|---|
|
| |||
| Problems in chewing | 0.46 | 10 | 16 |
| Eating slower than others | 0.45 | 14 | 22 |
| Biting hard food | 0.64 | 14 | 18 |
| Pain while eating | 0.83 | 14 | 15 |
| Limited mouth opening | 0.87 | 11 | 14 |
|
| |||
| MMO limited* | 0.42 | 12 | 15 |
| Crepitation (audible) | 0.0 | 5 | 7 |
| Pain MMO | 0.73 | 18 | 11 |
| Deviation MMO (>2 mm) | 0.31 | 7 | 15 |
|
| |||
| Asymmetry | 0.25 | 22 | 19 |
| Retrognathia | 0.25 | 16 | 8 |
| TMJ involv. RE vs Rha | 0.46 | 54 | 51 |
| ICC MMO Rh vs RE | 0.61 (p < 0.01) | ||
| Δ MMORh - MMORE ≤7 mm [n (%)] | 50 (67.6%) | ||
| μ Δ MMO Rh vs RE [mm] | 0.9 (p = 0.35) | ||
History related items (n = 5), examination related items (n = 4), and inspection related items (n = 2) compose the screening protocol. Intraclass correlation of the rheumatologist and the reference examiner.
RE: reference examiner. ICC: intraclass coefficient.
*MMO limited: ≤ 35 mm (≤10 yrs); ≤ 40 mm (>10 yrs); a TMJ involvement based on the criterion ‘at least 1 positive score. μ = mean, p value Δ MMO (Students t-test)
Pearson correlation of TMJ protocol variables and JADAS-27 for the rheumatologist and the reference examiner
|
|
|
|
|---|---|---|
| Pain on MMO – JADAS-27 | 0.21 (0.08) | 0.51 (<0.01) |
| Pain on chewing – JADAS-27 | 0.47 (<0.01) | 0.19 (<0.01) |
| Total score – JADAS-27 | 0.34 (0 | 0.49 (<0.01) |
| Fh° – JADAS-27 | 0.36 ( | 0.47 (<0.01) |
| Fe* – JADAS-27 | 0.26 (0.03) | 0.44 (<0.01) |
| MMO – JADAS-27 | - 0.27 (0.03) | - 0.23 (0.08) |
°Fh: number of positive history scores on mandibular function; *Fe: number of positive examination scores on mandibular function. Rh: rheumatologist; RE: reference examiner; correlation r values; p: probability (Students t-test).
Test characteristics of the TMJ protocol for different cut-off points; assessments by the rheumatologist
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
|
| |||||||
|
| 34 | 40 | |||||
| JADAS-27 (sd) | 2.0 (2.98) | 5.0 (7.13) | 0.029 | ||||
| JADAS-27 ≥ 2 | 0.65 | 0.55 | 0.55 | 0.65 | |||
| JADAS-27 ≥ 3.8 | 0.65 | 0.51 | 0.38 | 0.77 | |||
|
| |||||||
|
| 49 | 25 | |||||
| JADAS-27 (sd) | 2.2 (3.12) | 6.39 (8.36) | 0.003 | ||||
| JADAS-27 ≥ 2 | 0.47 | 0.78 | 0.64 | 0.63 | |||
| JADAS-27 ≥ 3.8 | 0.57 | 0.77 | 0.52 | 0.80 | |||
|
| |||||||
|
| 60 | 14 | |||||
| JADAS-27 (sd) | 2.37(3.14) | 8.94 (10.2) | < 0.001 | ||||
| JADAS-27 ≥ 2 | 0.41 | 0.85 | 0.70 | 0.63 | |||
| JADAS-27 ≥ 3.8 | 0.52 | 0.84 | 0.60 | 0.80 | |||
|
| |||||||
|
| 64 | 10 | |||||
| JADAS-27 (sd) | 3.31 (5.69) | 5.56 (6.26) | 0.306 | ||||
| JADAS-27 ≥ 2 | 0.18 | 0.90 | 0.60 | 0.56 | |||
| JADAS-27 ≥ 3.8 | 0.22 | 0.90 | 0.50 | 0.72 |
JADAS-27: juvenile arthritis disease activity score. Sens: sensitivity; Spec: specificity; NPV: negative predictive value; PPV: positive predictive value. p: probability (Students t-test).